Advances in treating CMV.
Long-awaited results from a study of treating CMV (cytomegalovirus) retinitis show that a new formulation of oral (by mouth) ganciclovir, known as valganciclovir, is as effective as the intravenous (IV, injection into the vein) version of the drug. This is the first time that an oral drug for treating CMV has been shown to be as effective as the IV version.
D000998:Antiviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D000077562:Valganciclovir
D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir